

SWL ICS Wound Management Steering Group

Terms of Reference

1. Introduction

South West London (SWL) integrated care system (ICS) was established in July 2022 in response to [Integrating care next steps to building strong and effective integrated care systems across England](#) and the [Integrated Care Systems: design framework](#). SWL ICS has four key objectives:

- Improve outcomes in population health and healthcare
- Tackle inequalities in outcomes, experiences and access
- Enhance productivity and value for money
- Help the NHS support broader social and economic development.

South West London Wound Management Steering Group provides recommendations on wound care products included in the SWL Joint Formulary.

Partner organisations participating in SWL wound care steering group include: Croydon, Kingston, Merton, Richmond, Sutton and Wandsworth “Places”, Croydon Health Services NHS Trust, Epsom and St Helier University Hospitals NHS Trust, Kingston Hospital Foundation NHS Trust, St George’s University Hospitals NHS Foundation Trust, South West London and St George’s Mental Health NHS Trust, Central London Community Healthcare NHS Trust, Your Healthcare Community Interest Company (CIC), Hounslow and Richmond Community Healthcare NHS Trust, Sutton Health and Care (Epsom and St Helier University Hospitals NHS Trust).

2. Remit

- To optimise wound management across SWL ICS.
- Assessment of new dressings and products supporting evidence-based, cost-effective, peer-reviewed wound care choices and treatment plans (see Appendix 1 – SWL Joint Formulary Wound Management Review Process and SWL SOP for wound management evaluation).
- To oversee the governance arrangements for the wound care section of the South West London Joint Formulary.
- To maintain, implement, monitor and evaluate the wound care section of the [South West London Formulary \(swljointmedicinesformulary.nhs.uk\)](#).
- To maintain, monitor and review wound management resources on the SWL IMO Webpage (<https://swlimo.southwestlondon.icb.nhs.uk/clinical-guidance/wound-care/>)
- Education and training on wound management & related products, which will support the above formulary and resources developed.
- To develop care pathways for management of wounds to support new dressing applications, when necessary, to improve patient care and experience.
- To enable partnership working to highlight unwarranted variation in prescribing of wound care products and to ensure patients have consistent access to these with

safe, clinically and cost-effective outcomes representing value for money across care pathways involving multiple providers, facilitated through collaborative working.

- To lead on the development of initiatives to reduce spend on wound management where appropriate.

3. Governance and Authority

The SWL Wound Management Steering Group will be accountable to and operates under the oversight of the South West London Integrated Medicines Optimisation Committee (IMOC).

The SWL Wound Management Steering Group will report to the South West London Joint Formulary Committee (JFC) and provide evidence-based wound management recommendations using Appendix 1 - SWL Joint Formulary – Wound Management Section Review Process. Formulary recommendations will be presented to SWLJFC for ratification. Minutes from the applicable Wound Care Steering Group Meeting will be sent to SWLJFC.

- Applications will be in the format of:
 - Formulary amendment application (for most dressings)
 - Full application for evaluation for new technologies and other products deemed appropriate by the steering group

SWL JFC will provide a report on formulary decisions to [SWL IMOC](#) for information and advise when further discussion and decision is required at SWL IMOC in the areas 3.1 to 3.4 below:

3.1 Affordability: Where the cost impact is likely to be significant to the local health economy. Cost impact assessment would include both medicines costs and activity costs

3.2 Identified Population Need: Where the intervention is likely to have a high impact for the needs of the population, further discussion on implementation

3.3 Further Partnership Discussion: A major change in the care pathway or model of care is required

3.4 Reputation Risk: Where there is likely to be a high risk of challenge to decision making and a discussion on mitigation at SWL IMOC would reduce this risk.

All SWL pathways/policies relating to wound care will be approved at SWL IMOC following JFC formulary approvals. This steering group will develop pathways supported as appropriate by task and finish groups using the IMOC policy/guideline development process.

- Minor change in pathway representing low clinical and financial risk, and where a full consensus has been reached at the network group, the pathway will be approved by SWL IMOC, either by consultation with members or by chair's action.
- Significant change in the pathway in the areas 3.1 to 3.4 above will be discussed and approved at SWL IMOC

SWL IMOC will use a prioritisation approach to make recommendations on the use of medicines across the whole health economy in SWL, taking into account the financial position of partner organisations. Where a medicine is not subject to NICE Technology

appraisal, it will be compared with existing interventions and other competing service developments. Funding will depend on priority and affordability either through investment or disinvestment within the health economy.

Pathways, Policies and Guidelines relating to Wound care will be presented to SWLIMOC for approval following the process [About us – SW London Integrated Medicines Optimisation Committee \(icb.nhs.uk\)](#)

4. Membership

Lead Pharmacist(s), SWL ICB
Senior Primary Care Pharmacist(s), SWL ICB
Tissue Viability Nurse, Croydon
Tissue Viability Nurse, Your Healthcare CIC
Tissue Viability Nurse, Kingston Hospital
Tissue Viability Nurse, Central London Community Healthcare NHS Trust
Tissue Viability Nurse, Hounslow and Richmond Community Healthcare NHS Trust
Tissue Viability Nurse, Sutton Health & Care
Tissue Viability Nurse, Epsom and St Helier Hospital
Lead Clinical Nurse in Plastic Surgery, St Georges University Hospital NHS Trust
Tissue Viability Nurse, St Georges University Hospital NHS Trust
Tissue Viability Nurse, South West London and St Georges Mental Health Trust
Podiatry representatives(s), South West London
GP Practice Nurses, South West London – by invite when necessary
District Nurses, South West London – by invite when necessary
Hospital Nurses – by invite

Members have the responsibility of contributing to and participating in the activities and should ensure that the clinical and operational perspectives of their organisation are considered within all decisions.

Each member should seek to attend every SWL JFC meeting, or send a representative.

5. Frequency

6 monthly.

6. Quoracy

Representation from each of the Providers is required to conduct the meeting plus at least one lead/senior pharmacist from primary care.

7. Decision making

Decisions will be reached by consensus. In cases where there is no consensus, a majority vote from the committee is required for a decision. All voting members present will have voting rights where a vote is required.

Decisions made will be accurately recorded in the minutes .

Document History

Version: V 2

Author: SWL Wound Management Steering Group

Approved by: SWL Integrated Medicines Optimisation Committee

Approval date: 17/04/2024
Review Date: 17/04/2026

Appendix 1: SWL Joint Formulary – Wound Management Section Review Process

When to review	<p>Recommendations will be reviewed in response to significant changes in the evidence base. A product may be removed from the formulary or the restricted prescribing status may be amended in accordance with new evidence. This may include:</p> <ul style="list-style-type: none"> - NICE technology appraisal recommendations - Regional Medicines Optimisation Committee recommendations - A significant change in the evidence base - A change in licensing status - Review of local care pathways - Safety guidance - In use safety/compliance issues
Frequency of Review	Every 12 months (or sooner if clinical need arises)
Scope of Review	<p>The following information sources will be used:</p> <ul style="list-style-type: none"> -NICE Technology Appraisals -NICE Clinical Guidelines -NICE Evidence Summaries -NICE Accredited resources -MHRA Safety Updates
Identification of Priorities	<p>Wound Care Steering Group members will prioritise medicines not subject to a NICE technology appraisal for consideration by the group using the following criteria:</p> <ul style="list-style-type: none"> - Impact on patient care - Timelines for new medicines reaching the market - Severity of disease and patient numbers affected - Clinical effectiveness - Patient safety - Gaps in treatment or other available treatments - Cost effectiveness - Resource impact - Inappropriate variation in local current practice

<p>Application Process – in line South West London Integrated Care System (SWL ICS) Joint Medicines Formulary Management policy</p>	<ul style="list-style-type: none"> - Only a wound care specialist (e.g. tissue viability nurse, podiatrist) employed on a permanent basis by an NHS Provider in SWL can make a formulary application for a product to be considered - Complete the wound care product screening tool in the SOP for wound management review process and send to pharmacist representative for addition to the wound management steering group agenda. As SWL wound care steering group will make decisions for the health care community in SW London, all applications require stakeholder engagement with clinical services at other SWL providers in order to reach a consensus on the application. This promotes best practice and improves quality and consistency of care across SW London and is in line with SWL pathway work. Evidence to support the use of the wound management products, including clinical effectiveness and safety, should be reviewed by the applicant before submission. There must be an adequate evidence base to support clinical effectiveness of a new medicine. Applications unsupported by evidence are unlikely to be approved. - Any local critical appraisal and evidence synthesis will assess the following domains in accordance with the Appendix 1 - SWL Ethical Decision Making Framework : <ul style="list-style-type: none"> - patient safety - clinical effectiveness - cost effectiveness or resource impact (link with London Procurement Partnership/local ePACT2 data) - strength of evidence - place in therapy relative to available treatments - national guidance and priorities - local health priorities - equity of access - The Wound Management Steering Group will assess applications using the above criteria and may request an in-use review of the product suitability as per SWL SOP for wound management evaluation. - Recommendations made for inclusion in the formulary will be presented to the SWL Joint Formulary Committee for ratification using the appropriate forms.
---	---